Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) issued its earnings results on Monday. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.23, Zacks reports. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 122.00%.
Vivos Therapeutics Trading Down 16.1%
Shares of VVOS traded down $0.02 during trading hours on Monday, reaching $0.08. The stock had a trading volume of 4,970,300 shares, compared to its average volume of 4,962,193. Vivos Therapeutics has a 12 month low of $0.07 and a 12 month high of $2.69. The firm has a 50-day simple moving average of $0.14 and a 200 day simple moving average of $0.66. The company has a market capitalization of $1.65 million, a price-to-earnings ratio of -0.04 and a beta of 6.37.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $2.80.
Check Out Our Latest Stock Report on VVOS
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.
Read More
- Five stocks we like better than Vivos Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
